Ultimovacs finalize topline data for ph2 cancer vaccine trial
Ultimovacs is a norwegian clinical phase biotech with a universal cancer vaccine as its lead product.
Today the company reported to the market that in march it will share topline data from its randomized phase 2 trial INITIUM for its lead product UV1, a universal cancer vaccine to be used in combination with checkpoint inhibitors.
The stock is at the moment testing the last major resistance level at around NOK 140, before the way is open to a retest of ATH.
Today the company reported to the market that in march it will share topline data from its randomized phase 2 trial INITIUM for its lead product UV1, a universal cancer vaccine to be used in combination with checkpoint inhibitors.
The stock is at the moment testing the last major resistance level at around NOK 140, before the way is open to a retest of ATH.